Monoclonal antibody-drug conjugateFDA-approvedSecond-line
Ado-trastuzumab emtansine
How it works
Delivers a toxic agent directly to HER2-positive cancer cells, killing them.
Cancer types
Breast Cancer— HER2-positive
Efficacy
In clinical trials, around 33% of patients with HER2-positive breast cancer who received ado-trastuzumab emtansine experienced a complete response, with a median overall survival of approximately 22 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Cost-effectiveness of trastuzumab deruxtecan in Finland | Breast Cancer | phase-3 | Total quality-adjusted life years (QALYs) and life years (LYs) gained for T-DXd compared with T-DM1 were 1.93 and 2.56, respectively. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.